← All trials
NCT07203755
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 22, 2025
- Primary completion
- Feb 28, 2029
- Completion date
- Feb 28, 2029
- First posted
- Oct 2, 2025
- Last posted
- Oct 2, 2025
- Enrollment
- 260
- Arms / groups
- 11 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Tianjin Cansino Biotechnology IncLead sponsor
- Government of ChinaOfficial
Drugs studied
- DTaP, inactivated poliovirus, haemophilus influenzae b conjugate, hepatitis b vaccine
- meningococcal (groups A, C, Y, W) CRM197 conjugate vaccine
- Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
- meningococcal (groups A, C, Y, W) tetanus toxoid conjugate vaccine
- haemophilus influenzae type b conjugate vaccine
- acellular pertussis vaccine (including diptheria and tetanus toxoids)
- sodium chloride
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.